🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06468852
Recruiting Not applicable

GDFT on the Postoperative Outcome in Head and Neck Cancer Surgery

NCT06468852 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tongren Hospital
Phase
Not applicable
Started
2024-05-16
Last updated
2024-06-21

Condition(s) studied

Postoperative Complications

Investigational drug(s) / intervention(s)

Goal-Directed Fluid Therapy

Goal-Directed Fluid Therapy: Stroke volume variation (SVV)≤12% and cardiac index (CI)≥2.5L/min/m2 are the goals of Goal-Directed fluid therapy, while the mean arterial pressure (MAP) are kept between 65 and 90 mmHg. 5mL/kg of crystalloids will be infused during induction period, followed by an infusion rate of 2 mL/kg/h to supplement the physiological requirements. If SVV\>12% for more than 5 min, a 250 mL bolus of colloid is given. Another 250 ml bolus of colloid is administrated if SVV was still more than 12% or SV decreased over 10%. If the CI\<2.5 L/min/m2, inotropes are used to achieve this minimum CI, serving as a safety parameter to prevent the patient from being exposure to a low cardiac output state. If SVV and CI reached the s target range but MAP could not maintain the expected level, vasopressors were started. Assess the patients every 5min intraoperatively to ensure that all parameters adhere to the target range according to the study algorithm.

Study summary

The goal of this clinical trial is to evaluate whether goal-directed fluid therapy (GDFT) can improve the postoperative recovery in patients undergoing head and neck cancer surgery. It aims to answer is:

• Whether GDFT can reduce the occurrence of serious postoperative complications? Researchers will compare GDFT protocol to a standard conventional fluid therapy in head and neck cancer surgery to see if GDFT strategy works to improve the postoperative recovery.

Participants will

* Receive GDFT protocol or a conventional fluid therapy during the surgery.
* Be continuously follow-up during hospitalization and after discharge to record the occurrence of postoperative complications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Adult patients (Age≥18) * Scheduled to undergo head and neck cancer surgery (including nasopharyngeal carcinoma, laryngocarcinoma, hypopharyngeal carcinoma, and other head and neck malignancies, but not thyroid cancer) with an expected duration of 2 hours or longer * Agree to receive invasive artery blood pressure monitoring Exclusion Criteria: * American Society of Anesthesiologists (ASA) classification\>Ⅳ * Palliative surgery was performed for the terminal tumors * Microlaryngoscopic laser surgery or endoscopic surgery * Underwent major thoracic or abdominal surgery within 30 days * Regular renal replacement therapy is required * NYHA grade\>3 or ejection fraction \<30% * Lung disease does not tolerate the tidal volume by 8 ml/kg * Atrial fibrillation * Unable to give informed consent * pregnant or lactating woman * Emergency surgery

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing tongren Hospital, Capital Medical University Beijing Beijing Municipality Recruiting

More Beijing Tongren Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06468852 on ClinicalTrials.gov ↗ ← All trials in China